Form 4: Leap Therapeutics Announces Chief Operating Officer Augustine Lawlor's Departure
Officer Departure Notification
Augustine Lawlor has ceased serving as Chief Operating Officer of Leap Therapeutics, Inc., effective June 30, 2025, and is no longer subject to Section 16 reporting requirements.
Summary
- Augustine Lawlor is no longer serving as the Chief Operating Officer of Leap Therapeutics, Inc. (LPTX).
- The change in his role became effective on June 30, 2025.
- As a result of his departure, Augustine Lawlor is no longer subject to Section 16 of the Securities Exchange Act of 1934.
- He will no longer be required to report transactions in Leap Therapeutics, Inc. equity securities on Form 4 or Form 5.
Sentiment
Score: 5
Explanation: The document reports a standard executive personnel change without providing context that would indicate a positive or negative impact on the company's operations or outlook.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the company's operations or financial performance.
Industry Context
This filing is a standard regulatory disclosure for a change in executive personnel, common across all industries, including the biotechnology sector where Leap Therapeutics operates. It does not provide specific insights into broader industry trends or competitive landscape.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | Augustine Lawlor | N/A | 06/30/2025 | Departure from role |
Stakeholder Impact
- Shareholders: The departure of a Chief Operating Officer may lead to questions regarding operational continuity, but this filing provides no further context.
- Employees: Potential internal restructuring or changes in leadership within the operations department may occur.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Effective date of Augustine Lawlor's departure as Chief Operating Officer of Leap Therapeutics, Inc. |
| 07/01/2025 | Date the Form 4 was signed by Douglas E. Onsi, as attorney-in-fact for Augustine Lawlor. |
Keywords
Leap Therapeutics, LPTX, Augustine Lawlor, Chief Operating Officer, COO, Management Change, SEC Form 4, Section 16, Executive Departure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.